
|Articles|November 21, 2017
OmniComm Systems Signs Letter of Intent to Acquire Assets of Algorithm and its Algorics
Advertisement
OmniComm Systems, Inc. and Algorithm, Inc. have signed a letter of intent, under which OmniComm will acquire assets and assume liabilities of Algorics to build upon RBM and data analytics. By combining forces, the companies expect increased operating efficiency, strengthened traction in the risk-based approach solution area, new marketing opportunities, an expanded portfolio of electronic data capture solutions for the clinical trials industry, and will provide OmniComm with access to advanced analytics and algorithms.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Syneos Health Expands AI Ecosystem With Three New Platform Partnerships
2
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations
3
When the Slack Runs Out: AI and the CRO Operating Model
4
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment
5




